EA201390832A1 - Bifidobacterium cect 7765 и его применение для предотвращения и/или лечения избыточного веса, ожирения и сопутствующих заболеваний - Google Patents

Bifidobacterium cect 7765 и его применение для предотвращения и/или лечения избыточного веса, ожирения и сопутствующих заболеваний

Info

Publication number
EA201390832A1
EA201390832A1 EA201390832A EA201390832A EA201390832A1 EA 201390832 A1 EA201390832 A1 EA 201390832A1 EA 201390832 A EA201390832 A EA 201390832A EA 201390832 A EA201390832 A EA 201390832A EA 201390832 A1 EA201390832 A1 EA 201390832A1
Authority
EA
Eurasian Patent Office
Prior art keywords
obesity
prevention
treatment
overweight
application
Prior art date
Application number
EA201390832A
Other languages
English (en)
Inventor
Иоланда Санс Эрранс
Иоланда Арлетте Сантакрус
Паола Гауффин
Original Assignee
Консехо Супериор Де Инвестигасионес Сьентификас К.С.И.С.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Консехо Супериор Де Инвестигасионес Сьентификас К.С.И.С. filed Critical Консехо Супериор Де Инвестигасионес Сьентификас К.С.И.С.
Publication of EA201390832A1 publication Critical patent/EA201390832A1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A61K35/745—Bifidobacteria
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
    • C12N1/205—Bacterial isolates
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2400/00—Lactic or propionic acid bacteria
    • A23V2400/51—Bifidobacterium
    • A23V2400/535—Pseudocatenulatum
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
    • C12R2001/00—Microorganisms ; Processes using microorganisms
    • C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Mycology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Diabetes (AREA)
  • Biochemistry (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Virology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Nutrition Science (AREA)
  • Polymers & Plastics (AREA)
  • Food Science & Technology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Emergency Medicine (AREA)

Abstract

Настоящее изобретение относится к штамму BifidobacteriumСЕСТ 7765, его клеточным компонентам, метаболитам и молекулам секреции, их сочетаниям с другими микроорганизмами, и к композициям, включающим указанные выше компоненты, а также к применению штаммов вида Bifidobacteriumpseudocatenulatumили к применению штамма СЕСТ 7765 для предотвращения и/или лечения ожирения, избыточного веса, гипергликемии и диабета, предпочтительно, сахарного диабета 2-го типа, жирового гепатоза или жировой дистрофии печени, дислипидемии, метаболического синдрома, нарушений функций иммунной системы, связанных с ожирением и избыточным весом; и нарушений композиции кишечной микрофлоры, связанных с ожирением и избыточным весом.
EA201390832A 2010-12-07 2011-12-07 Bifidobacterium cect 7765 и его применение для предотвращения и/или лечения избыточного веса, ожирения и сопутствующих заболеваний EA201390832A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
ES201031811A ES2389547B1 (es) 2010-12-07 2010-12-07 Bifidobacterium cect 7765 y su uso en la prevención y/o tratamiento del sobrepeso, la obesidad y patologías asociadas.
PCT/ES2011/070838 WO2012076739A1 (es) 2010-12-07 2011-12-07 Bifidobacterium CECT 7765 y su uso en la prevención y/o tratamiento del sobrepeso, la obesidad y patologías asociadas

Publications (1)

Publication Number Publication Date
EA201390832A1 true EA201390832A1 (ru) 2013-12-30

Family

ID=46206648

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201390832A EA201390832A1 (ru) 2010-12-07 2011-12-07 Bifidobacterium cect 7765 и его применение для предотвращения и/или лечения избыточного веса, ожирения и сопутствующих заболеваний

Country Status (14)

Country Link
US (1) US20140369965A1 (ru)
EP (1) EP2650002A4 (ru)
JP (1) JP2014505467A (ru)
KR (1) KR20140147656A (ru)
CN (1) CN103619343A (ru)
AR (1) AR084215A1 (ru)
AU (1) AU2011340460A1 (ru)
BR (1) BR112013014193A2 (ru)
CA (1) CA2824619A1 (ru)
EA (1) EA201390832A1 (ru)
ES (1) ES2389547B1 (ru)
MX (1) MX2013006460A (ru)
TW (1) TW201305333A (ru)
WO (1) WO2012076739A1 (ru)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201112091D0 (en) 2011-07-14 2011-08-31 Gt Biolog Ltd Bacterial strains isolated from pigs
GB201117313D0 (en) 2011-10-07 2011-11-16 Gt Biolog Ltd Bacterium for use in medicine
US20150283144A1 (en) * 2012-11-01 2015-10-08 Rijksuniversiteit Groningen Methods and compositions for stimulating beneficial bacteria in the gastrointestinal tract
GB201306536D0 (en) 2013-04-10 2013-05-22 Gt Biolog Ltd Polypeptide and immune modulation
EP3007723A1 (en) * 2013-06-12 2016-04-20 University College Cork, National University Of Ireland Bile salt hydrolase bsh1 for regulating weight gain, serum cholesterol levels, and liver triglycerides in a mammal; bacteria strains expressing bsh1 variants
JP6382027B2 (ja) * 2014-08-26 2018-08-29 サンスター株式会社 ビフィズス菌及びアブラナ科野菜を含有する経口組成物
SG10202105996WA (en) 2014-12-23 2021-07-29 4D Pharma Res Ltd Pirin polypeptide and immune modulation
KR20220151045A (ko) 2014-12-23 2022-11-11 4디 파마 리서치 리미티드 면역 조정
AU2016229982B2 (en) 2015-03-09 2020-06-18 Intekrin Therapeutics, Inc. Methods for the treatment of nonalcoholic fatty liver disease and/or lipodystrophy
PL3206700T3 (pl) 2015-06-15 2019-11-29 4D Pharma Res Ltd Kompozycje zawierające szczepy bakteryjne
RS59308B1 (sr) 2015-06-15 2019-10-31 4D Pharma Res Ltd Kompozicije koje sadrže bakterijske sojeve
MA41060B1 (fr) 2015-06-15 2019-11-29 4D Pharma Res Ltd Compositions comprenant des souches bactériennes
MA41010B1 (fr) 2015-06-15 2020-01-31 4D Pharma Res Ltd Compositions comprenant des souches bactériennes
MD3240554T2 (ro) 2015-06-15 2020-01-31 4D Pharma Res Ltd Blautia stercosis și wexlerae pentru utilizare în tratarea bolilor inflamatorii și autoimune
MY187060A (en) * 2015-06-30 2021-08-28 Perfect China Co Ltd Bifidobacteria as probiotic foundation species of gut microbiota
ME03003B (me) 2015-11-20 2018-10-20 4D Pharma Res Ltd Kompozicije koje sadrže bakterijske sojeve
GB201520497D0 (en) 2015-11-20 2016-01-06 4D Pharma Res Ltd Compositions comprising bacterial strains
GB201520638D0 (en) 2015-11-23 2016-01-06 4D Pharma Res Ltd Compositions comprising bacterial strains
GB201520631D0 (en) 2015-11-23 2016-01-06 4D Pharma Res Ltd Compositions comprising bacterial strains
CN105661547A (zh) * 2016-01-22 2016-06-15 湖南营养树科技有限公司 一种益生菌复配蚕桑的糖尿病人营养补充剂
GB201612191D0 (en) 2016-07-13 2016-08-24 4D Pharma Plc Compositions comprising bacterial strains
RS58869B1 (sr) 2016-03-04 2019-08-30 4D Pharma Plc Kompozicije koje sadrže blautia bakterijske sojeve za lečenje visceralne hipersenzitivnosti
TW201821093A (zh) 2016-07-13 2018-06-16 英商４Ｄ製藥有限公司 包含細菌菌株之組合物
EP3272396A1 (en) * 2016-07-18 2018-01-24 Bionou Research, S.L. Use of probiotics in the treatment and/or prevention of atopic dermatitis
EP3511407B1 (en) * 2016-09-06 2023-05-17 BGI Shenzhen Christensenella intestinihominis and application thereof
GB201621123D0 (en) 2016-12-12 2017-01-25 4D Pharma Plc Compositions comprising bacterial strains
CN110023484B (zh) * 2016-12-20 2022-11-08 深圳华大生命科学研究院 一种假小链状双歧杆菌及其培养方法和应用
MY197201A (en) * 2017-02-10 2023-05-31 Perfect China Co Ltd Novel probiotics bifidobacteria strains
BR112019020485A2 (pt) 2017-04-03 2020-05-12 Coherus Biosciences, Inc. Agonista ppary para tratamento de paralisia supranuclear progressiva
TWI787272B (zh) 2017-05-22 2022-12-21 英商4D製藥研究有限公司 包含細菌菌株之組合物
JP6978514B2 (ja) 2017-05-24 2021-12-08 フォーディー ファーマ リサーチ リミテッド4D Pharma Research Limited 細菌株を含む組成物
JP6884889B2 (ja) 2017-06-14 2021-06-09 フォーディー ファーマ リサーチ リミテッド４Ｄ Ｐｈａｒｍａ Ｒｅｓｅａｒｃｈ Ｌｉｍｉｔｅｄ 細菌株を含む組成物
KR20200015575A (ko) 2017-06-14 2020-02-12 4디 파마 리서치 리미티드 세균 균주를 포함하는 조성물
WO2019002612A1 (en) * 2017-06-30 2019-01-03 N.V. Nutricia SYMBIOTIC COMPOSITION FOR THE PREVENTION OF METABOLIC DISORDERS
EP3777868A4 (en) * 2018-03-23 2021-12-01 Morinaga Milk Industry Co., Ltd. COMPOSITION FOR INFANTS INTENDED TO PREVENT DISEASES CAUSED BY HYPERGLYCEMIA FROM SCHOOL AGE
WO2019227414A1 (zh) * 2018-05-31 2019-12-05 深圳华大生命科学研究院 一种组合物及其应用
ES2763874B2 (es) * 2018-11-30 2020-10-13 Consejo Superior Investigacion Phascolarctobacterium faecium para su uso en la prevencion y tratamiento de la obesidad y sus comorbilidades
CN109486715B (zh) * 2018-12-07 2022-07-15 江苏靶标生物医药研究所有限公司 一种富硒长双歧杆菌及其制备方法和应用
CN110604749B (zh) * 2019-08-30 2020-08-14 北京农学院 动物双歧杆菌a12及其在控制糖尿病或高血脂症特别是体重增加或肥胖中的应用
CN110894481B (zh) * 2019-12-09 2023-06-27 毕德玺 一株假链状双歧杆菌及其应用
KR102629635B1 (ko) * 2021-05-13 2024-01-30 주식회사 비티진 신규한 비피도박테리움 롱검 균주 및 이의 용도
WO2023118868A1 (en) * 2021-12-21 2023-06-29 Quadram Institute Bioscience Bifidobacterium and compositions thereof for breast cancer treatment
CN115466689B (zh) * 2022-02-09 2023-06-16 中国科学技术大学 用于预防和/或治疗代谢类疾病的益生菌组合物及其应用
CN115948273B (zh) * 2022-06-21 2023-07-18 合肥瀚微生物科技有限公司 治疗糖尿病及相关病症的两歧双歧杆菌
WO2024058984A2 (en) * 2022-09-16 2024-03-21 MarvelBiome, Inc. Methods and uses of microbiome compositions, components, or metabolites for treating insulin-associated diseases

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH10306028A (ja) 1997-05-06 1998-11-17 Koji Haraguchi 脂質消化吸収阻害整腸剤
JP4580542B2 (ja) 2000-05-17 2010-11-17 株式會社バイオニア 肥満又は糖尿病治療用微生物及びその微生物を含む医薬組成物
US20030092163A1 (en) * 2001-07-26 2003-05-15 Collins John Kevin Probiotic bifidobacterium strains
AU2002341384A1 (en) * 2001-09-05 2003-03-24 Actial Farmaceutica, Lda. Lactic acid bacteria comprising unmethylated cytosine-guanine dinucleotides for use in therapy
TW200719833A (en) 2005-03-24 2007-06-01 Suntory Ltd Novel microorganism and method of processing fresh coffee beans by using the same
SE529185C2 (sv) * 2005-10-07 2007-05-22 Arla Foods Amba Användning av probiotiska bakterier för tillverkning av livsmedel eller läkemedel för förhindrande av övervikt
WO2007085970A2 (en) 2006-01-27 2007-08-02 Danisco A/S Use of probiotic microorganisms for the treatment and prevention of obesity and related disorders
EP1974734A1 (en) 2007-03-28 2008-10-01 Nestec S.A. Probiotics for reduction of risk of obesity
CA2681935A1 (en) 2007-03-30 2008-10-09 Baker Medical Research Institute Treatment of obesity
US20110189149A1 (en) * 2008-06-20 2011-08-04 Remy Burcelin New Uses of Lactic Acid Bacteria and Bifidobacteria
EP2213286A1 (en) 2009-02-02 2010-08-04 Zeltia, S.A. N-(phenyl or pyridyl)prenylamine derivatives for the treatment of obesity, diabetes and cardiovascular diseases

Also Published As

Publication number Publication date
AU2011340460A1 (en) 2013-07-11
ES2389547A1 (es) 2012-10-29
ES2389547B1 (es) 2013-08-08
BR112013014193A2 (pt) 2016-09-13
US20140369965A1 (en) 2014-12-18
CN103619343A (zh) 2014-03-05
AR084215A1 (es) 2013-05-02
EP2650002A1 (en) 2013-10-16
KR20140147656A (ko) 2014-12-30
TW201305333A (zh) 2013-02-01
EP2650002A4 (en) 2014-08-13
CA2824619A1 (en) 2012-06-14
MX2013006460A (es) 2013-10-25
WO2012076739A1 (es) 2012-06-14
JP2014505467A (ja) 2014-03-06

Similar Documents

Publication Publication Date Title
EA201390832A1 (ru) Bifidobacterium cect 7765 и его применение для предотвращения и/или лечения избыточного веса, ожирения и сопутствующих заболеваний
CL2009000905A1 (es) Composicion comestible que comprende bifidobacterium longum atcc baa-999; y su uso para tratar o prevenir la ansiedad y/o desordenes relacionados con ansiedad.
MX2018009945A (es) Composiciones y metodos novedosos para el tratamiento de las enfermedades relacionadas con la inmunidad.
MX367132B (es) Nueva cepa de bifidobacterium animalis subsp. lactis cect 8145 y su uso para el tratamiento y/o prevencion de sobrepeso y obesidad y enfermedades asociadas.
AU2012253759A8 (en) Tricyclic sulfonamide compounds and methods of making and using same
MY162511A (en) Engineered anti-tslp antibody
BR112012013431A2 (pt) composto, composição farmacêutica e seu uso
UA109123C2 (uk) Пробіотична композиція для застосування в лікуванні запалення кишечнику
EA201190217A1 (ru) Замещенные 2-ацетамидо-5-арил-1,2,4-триазолоны и их применение
AU2012253757A8 (en) Partially saturated tricyclic compounds and methods of making and using same
BR112012011478A2 (pt) composições fosfolipídicas terapêuticas concentradas.
EP2576578A4 (en) POLYMORPHES OF 2'-O-FUCOSYLLACTOSE AND MANUFACTURE THEREOF
MX2021000715A (es) Composiciones y metodos para tratar trastornos metabolicos.
WO2019066577A3 (ko) 짧은 사슬 지방산 생성 장내 세균 군집의 변화를 이용한 알코올성 간 질환의 진단 및 치료용 조성물
EA201171339A1 (ru) Способ снижения внутриглазного давления у людей
MX342947B (es) Tratamiento de diabetes tipo 2.
WO2012049307A3 (en) Novel n-terminally modified insulin derivatives
AU2010286532A8 (en) Methods of treatment using anti-oxidized LDL antibodies
WO2006046871A3 (en) Peri-operative composition comprising lactobacillus rhamnosus
AU2012334804A8 (en) Modulators of C3a receptors
WO2008112840A3 (en) Novel composition and methods for the treatment of immune related diseases
MX2009013126A (es) Nuevos compuestos 892.
BR112013032992A2 (pt) composições de gordura vegetal hidrogenada
WO2013084070A3 (en) Salmonella vaccine proteins
BR112013030308A2 (pt) composição de oligossacarídeos para prevenir ou reduzir o risco de síndrome metabólica